SecBot SecBot

RCKT drug pipeline

$2.16
−6.1% 1-day · Nov 16
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
±3.7%
1-day, median of 16 events
IV rank
No data
No current options data
Rated drugs
4
4 neutral
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
● neutral
Impact
PhaseApproved (FDA accelerated approval)
Time to marketAlready FDA-approved (March 26, 2026); commercial launch underway

KRESLADI marnetegragene autotemcel Updated Jun 30

What to watch

KRESLADI's approval and the $180M PRV sale provide a cash runway into Q2 2028, but the drug is an ultra-orphan gene therapy with a "minimal viable launch", not a major revenue generator. Watch the company's cardiovascular pipeline (RP-A501 for Danon disease, RP-A701 for BAG3 cardiomyopathy) for future catalysts. RCKT carries heavy short interest (~25.5% of float), a squeeze risk if pipeline data hits, but the clinical hold history on RP-A501 adds risk.

Bull case
  • KRESLADI is the first and only FDA-approved gene therapy for severe LAD-I, a true breakthrough for an ultra-rare, fatal pediatric disease with no adequate treatment alternative for patients without a matched bone marrow donor.
  • The $180M sale of the rare pediatric disease PRV (closed June 12, 2026) provides substantial non-dilutive capital, extending Rocket's cash runway into Q2 2028 and de-risking the company's near-term financing needs.
  • The Phase 1/2 data showed 100% overall survival for all treated patients with no treatment-related serious adverse events, a compelling efficacy/safety profile for a fatal disease where the alternative (allogeneic transplant) carries significant mortality risk.
Bear case
  • KRESLADI is an ultra-orphan drug, the CEO described it as a 'minimal viable launch' with annual treated patients expected to remain very low. It will not be a meaningful revenue driver regardless of approval.
  • The stock dropped ~20% on the day of FDA approval (March 27, 2026), suggesting the market either expected more or is focused on pipeline risks at the company.
  • Rocket's other key pipeline asset, RP-A501 for Danon disease, has experienced serious clinical holds, one in May 2025 (patient death) and another noted in May 2026, creating significant binary risk for the stock's overall thesis.
● neutral
Impact
PhasePhase 2 (pivotal/registrational)
Time to marketIf the pivotal Phase 2 trial succeeds, a BLA submission for accelerated approval could follow in 2028-2029, given the 12-month endpoint timeline with last patient dosed by mid-2027.

RP-A501 Updated Nov 13

What to watch

Watch for updates on enrollment of the remaining 9 patients in the pivotal Phase 2 trial and any interim data presentations at medical conferences in 2027. The FDA alignment in September 2026 de-risked the regulatory path, but the stock near its 52-week low reflects lingering safety concerns and a long wait until topline data (likely 2028). KRESLADI commercial traction is a separate value driver that could support the stock in the interim.

Bull case
  • RP-A501 is the only gene therapy in clinical development for Danon disease, an ultra-rare, fatal genetic cardiomyopathy with no approved treatments -- a clear unmet need and potential orphan/breakthrough therapy advantages.
  • Phase 1 long-term data published in NEJM showed sustained reductions in LV mass index and cardiac biomarkers (cTnI reduced by 84%, NTproBNP by 57%) with preserved normal LVEF for up to 54 months.
  • FDA confirmed alignment on a pivotal pathway in September 2026, accepting a 12-patient efficacy population and 12-month co-primary endpoints intended to support potential accelerated approval.
Bear case
  • A patient death in May 2025 triggered an FDA clinical hold, and while the hold was lifted after a protocol amendment with recalibrated dosing, safety concerns remain a key overhang for the program.
  • The pivotal Phase 2 trial requires dosing 9 more patients by mid-2027, with 12-month co-primary endpoints, meaning topline data is likely not until 2028 -- a long wait with no near-term binary catalyst.
  • Insiders (General Counsel Wilson Martin and CEO Gaurav Shah) have been selling shares in recent months, which may signal limited confidence in the near-term outlook.
● neutral
Impact
PhasePhase 1
Time to marketLikely several years away, if successful. The program is still in Phase 1 with no Phase 2/3 design announced.

RP-A601 Updated Nov 13

What to watch

RP-A601 is an early-stage gene therapy program with encouraging but very preliminary Phase 1 data. The next meaningful catalyst is likely a regulatory update on Phase 2 trial design, which Rocket has not yet scheduled. Investors should watch for updates in Rocket's quarterly earnings calls and whether the company provides a timeline for advancing RP-A601 into a Phase 2/3 study. The stock's primary near-term value driver is RP-A501 for Danon disease, with pivotal Phase 2 data expected in early 2027.

Bull case
  • RP-A601 targets a validated genetic cause of a life-threatening heart disease with no approved disease-modifying therapies, representing a large unmet need. Preliminary Phase 1 data showed reductions in ventricular arrhythmia burden and improved quality-of-life measures. FDA has granted RMAT, Fast Track, and Orphan Drug designations, which could accelerate development and regulatory review. Rocket has a fully integrated gene therapy platform and manufacturing capabilities, with one product (KRESLADI) already FDA-approved.
Bear case
  • RP-A601 is still in early Phase 1 with no Phase 2/3 trial design announced, making it years away from any potential approval. The company's lead gene therapy program RP-A501 suffered a clinical hold and patient death in May 2025, raising safety concerns about the AAV9 platform more broadly. Rocket's cash runway extends only into Q2 2027 (roughly $188.9M as of year-end 2025), and the stock has fallen over 50% from its 52-week high. Tenaya Therapeutics' TN-401 is a direct competitor targeting the same PKP2 mutation and is already in Phase 1b/2. Insider selling has been ongoing, with the General Counsel and CEO both selling shares in recent months.
● neutral
Impact
PhasePhase 1
Time to marketAt least 5-7 years, assuming successful Phase 1 safety data, progression through Phase 2/3, and regulatory approval. The drug is currently in early Phase 1 with dosing just initiated.

RP-A701 Updated Nov 13

What to watch

The next catalyst for RP-A701 is initial safety and tolerability data from the Phase 1 study, though no specific readout date has been guided. Positive early data would validate Rocket's cardiovascular gene therapy platform beyond the lead RP-A501 program. However, the competing Affinia Therapeutics AFTX-201 program (Phase 1/2) is a direct rival and has already received FDA Fast Track and orphan drug designations, creating a competitive overhang.

Bull case
  • First-in-class AAVrh.74-based gene therapy for BAG3-associated dilated cardiomyopathy, a severe genetic heart condition with no approved disease-modifying therapies
  • FDA IND clearance obtained in June 2025 and Phase 1 dosing initiated as of Q3 2026, showing regulatory and clinical execution progress
  • EMA orphan designation granted October 20, 2026, providing European regulatory support and potential market exclusivity benefits
Bear case
  • Phase 1 only: RP-A701 is in early-stage clinical testing with no efficacy data yet, making it the highest-risk stage of drug development
  • Direct competition from Affinia Therapeutics' AFTX-201, which has FDA Fast Track and orphan drug designations and is already enrolling its Phase 1/2 UPBEAT trial for the same BAG3-DCM indication
  • Rocket's stock trades near its 52-week low ($2.325 vs $2.165 low) with a market cap under $300M, reflecting limited investor conviction in the broader pipeline

Past FDA events & how the stock moved

16 events
DateDrugEvent1 day5 days
Sep 15, 2026RP-A501Accelerated approval+1.5%−2.3%
Jun 12, 2026KRESLADIApproval+7.5%+30.1%
May 7, 2026RP-A501Clinical hold−6.0%−11.9%
Apr 28, 2026KRESLADIAccelerated approval−0.3%+1.4%
Mar 28, 2026KRESLADIPriority review−8.6%−8.2%
Mar 28, 2026KRESLADIPDUFA decision−8.6%−8.2%
Mar 27, 2026KRESLADIPriority review−26.6%−26.2%
Mar 27, 2026KRESLADIAccelerated approval−26.6%−26.2%
Mar 27, 2026KRESLADIOrphan drug designation−26.6%−26.2%
Mar 1, 2026KRESLADIAccelerated approval−0.8%−12.0%
Mar 1, 2026KRESLADIApproval−0.8%−12.0%
Feb 1, 2026RP-A501Clinical hold0.0%−9.2%
Jan 1, 2026RP-A501Clinical hold−1.4%+10.5%
Oct 14, 2025KRESLADIBLA filed+22.2%+14.7%
Oct 1, 2025KRESLADIBLA filed−1.5%+4.0%
Aug 1, 2025RP-A501Clinical hold+0.7%−6.2%